Biocon And Abraxis BioScience Launch ABRAXANE In India For Treatment Of Breast Cancer

[News]

Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, announced the launch of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant chemotherapy.

More... (http://www.medicalnewstoday.com/articles/115633.php)